Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00582387 · ClinicalTrials.gov registry record

Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer

A clinical trial of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

Completed
Registry status
116
Enrollment target
1
Study location

NCT00582387: Completed study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by Memorial Sloan Kettering Cancer Center.

NCT00582387 is a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 116 participants, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00582387, a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, has completed, sponsored by Memorial Sloan Kettering Cancer Center.

COMPLETED
Registry status
116 participants
Enrollment target
1
Study location

Study Summary

The purpose of the study is to see if we will be more able to tell what the risk is for bladder cancer to reoccur or worsen when genetics and risk factors are examined along with the stage and grade of the tumor. Superficial bladder cancer is a cancer that does not grow into the muscle layer of the bladder wall. Even though it is a superficial cancer, this type of cancer tends to come back after being treated and is often more aggressive when it returns. We already know, that the "stage" or how deeply the tumor grows into the bladder wall and the "grade" or how fast the tumor grows affect whether the tumor will come back or get worse over time. Now we use information about the stage and grade of your tumor to decide how to treat the tumor and how often you should be checked after the treatment is over. However, this has not been very reliable, because each person has unique genetic characteristics and other factors that are likely to affect what happens to the tumor over time. For instance, we know the risk for developing a cancer may be affected by your surroundings and other factors such as what you eat, the type of habits you have such as smoking, and the type of job you have, but not everyone exposed to the same risk factors gets a cancer. We believe this is due to unique genetic characteristics in each person which may help their body fight cancer.

Interventions

  • BEHAVIORAL questionnaires
  • GENETIC specimen samples

Study Locations (1)

New York

  • Memorial Sloan-Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 116 participants
Start Date 2004-03
Est. Completion 2013-07
Memorial Sloan Kettering Cancer Center

1,884 total trials

What the finished NCT00582387 record still lists

NCT00582387 is an observational study that tracks outcomes without assigning an intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 12,753-participant average among 175 other Bladder Cancer trials with a reported enrollment target (99% lower).

The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 2 interventions - of which questionnaires is the first listed.

NCT00582387 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT00582387 about?

NCT00582387 is a clinical study titled "Genetic Susceptibility to Tumor Recurrence and Progression in Patients With Non-Muscle Invasive Bladder Cancer". The purpose of the study is to see if we will be more able to tell what the risk is for bladder cancer to reoccur or worsen when genetics and risk factors are examined along with the stage and grade of the tumor. Superficial bladder cancer is a cancer that does not grow into the muscle layer of the ...

What is the current status of trial NCT00582387?

This trial is currently completed. The enrollment target is 116 participants. The study started on 2004-03. Estimated completion is 2013-07.

What conditions does trial NCT00582387 study?

This clinical trial studies the following conditions: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Urinary Cancer.

What interventions are being tested in trial NCT00582387?

The interventions under investigation include: questionnaires (BEHAVIORAL), specimen samples (GENETIC).

Who is sponsoring clinical trial NCT00582387?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00582387 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Bladder Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00582387's enrollment target sits among peer trials

116 80th of 175 higher than 96 of 175 other Bladder Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03014687 · 116 participants · Phase 4

    Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions

  • NCT03214562 · 116 participants · Phase 1

    Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

  • NCT03847467 · 116 participants · Phase 1

    Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy

  • NCT04222413 · 116 participants · Phase 1

    Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00582387, the US trial registry maintained by the National Library of Medicine. NCT00582387 (mid enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.